Nanosphere requests FDA approval for cardiac troponin I test
This article was originally published in Clinica
Nanosphere has submitted a 510(k) application to the US FDA for its cardiac troponin I test. It is designed to provide "early and sensitive" diagnosis of myocardial infarction (MI), and to stratify patients with acute coronary syndromes. Troponin is an established cardiovascular biomarker which is elevated during acute MI. The current gold-standard for diagnosis is troponin plus ECG, but there is a time lag of around four hours between MI occurring and troponin levels rising. Therefore researchers have suggested combining it with other biomarkers such as copeptin, or using more sensitive cardiac troponin assays (www.clinica.co.uk, September 3 2009).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.